Trials / Terminated
TerminatedNCT02740387
Open Label Study of OTO-104 in Subjects With Meniere's Disease
A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Otonomy, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a 1-year, multicenter, Phase 2, open-label safety study in subjects with unilateral Meniere's disease. Subjects will receive 1 intratympanic (IT) injection of 12 mg OTO-104 at 3-month intervals for a total of 4 injections total.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OTO-104 |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2016-04-15
- Last updated
- 2017-09-15
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02740387. Inclusion in this directory is not an endorsement.